Skip to main content
Fig. 8 | Journal of Experimental & Clinical Cancer Research

Fig. 8

From: TMEM52B suppression promotes cancer cell survival and invasion through modulating E-cadherin stability and EGFR activity

Fig. 8

Clinical significance of TMEM52B in human cancers. (A) Scatter plots examining TMEM52B mRNA expression (x-axis) and E-cadherin (left) or vimentin (right) mRNA expression (y-axis) from CCLE data (Broad, 2019). (B) Scatter plots examining TMEM52B mRNA expression (x-axis) and E-cadherin mRNA (left) or E-cadherin protein (right) expression (y-axis) from kidney renal clear cell carcinoma data (TCGA, Firehose Legacy). Correlations were statistically analyzed using the Pearson test. Equations were automatically generated using the cBioPortal webpage tool. (C) TMEM52B expression was correlated with the survival of cancer patients with tumors expressing low E-cadherin levels (below the median) when analyzed using the KM-Plotter. Kaplan-Meier analysis showed the probability of relapse-free survival from breast (n = 882), overall survival from lung (n = 571), post-progression survival from ovarian (n = 191), relapse-free survival from liver (n = 158), overall survival from rectal (n = 82), and overall survival from thyroid (n = 251) cancer patients data in relation to TMEM52B mRNA expression. TMEM52B expression was stratified as high vs. low according to an auto-select best cutoff value, and survival plots based on previously published data sets were generated using http://kmplot.com. P values were calculated by the Logrank test

Back to article page